Hemorif

Indications

This medication is prescribed for:

• Acute episodes of hemorrhoids.
• Chronic hemorrhoidal conditions.
• Chronic venous insufficiency in the lower limbs, characterized by symptoms such as leg heaviness, pain, and nocturnal cramps.

Ingredients

Each film-coated tablet contains:

• 450 mg of Diosmin (micronized BP)
• 50 mg of Hesperidin (micronized INN)

Each DS (double strength) film-coated tablet contains:

• 900 mg of Diosmin (micronized BP)
• 100 mg of Hesperidin (micronized USP)

Mechanism of Action

Diosmin and Hesperidin act as phlebotonic drugs and vascular protective agents. They enhance venous tone by prolonging the effects of noradrenaline, reducing venous capacitance, distensibility, and emptying time. These compounds also protect the microcirculation, reduce venous inflammation, normalize capillary permeability, and enhance lymphatic drainage.

Dosage

For Diosmin 450 mg & Hesperidin 50 mg:

• Acute hemorrhoidal attacks: Take 3 tablets twice daily for the first 4 days, followed by 2 tablets twice daily for 3 days, and then 1 tablet twice daily for maintenance.
• Chronic hemorrhoids: Take 1 tablet twice daily.
• Chronic venous insufficiency: Initially take 1 tablet twice daily for seven days; duration may be adjusted based on severity.

For Diosmin 900 mg & Hesperidin 100 mg:

• Acute hemorrhoids: Take 1 tablet thrice daily for the first 4 days, followed by 1 tablet twice daily for 3 days, then 1 tablet once daily for maintenance.
• Chronic hemorrhoids: Take 1 tablet once daily for 3 months.
• Chronic venous insufficiency: Take 1 tablet once daily for 2-6 months.
• Leg wounds: Take 1 tablet once daily for 2 months.

Administration

Take tablets with meals.

Interactions

No evidence of drug interactions has been reported in clinical trials.

Contraindications

This medication is contraindicated in individuals with hypersensitivity to any of its ingredients.

Side Effects

Reported side effects include gastric and neurovegetative disorders, which typically do not necessitate discontinuation of treatment.

Pregnancy & Lactation

Experimental studies have not shown teratogenic effects in animals. Breastfeeding is not recommended during treatment due to lack of data on excretion into breast milk.

Precautions & Warnings

If symptoms persist beyond 15 days, consult a physician. This medication is not recommended for patients with a history of cancer. No evidence of carcinogenicity or mutagenicity has been found in animal studies or clinical use.

Therapeutic Class

This medication belongs to the phlebotonic and vascular protective preparation class.

Storage

Store below 30°C, away from light and moisture, and out of reach of children.